Exosomes and the future of immunotherapy in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, associated with a late diagnosis and a five-year survival rate of 8%. Currently available treatments fall short in improving the survival and quality of life of PDAC patients. The only possible curative option is still the surgical re...
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
2019
|
| Assuntos: | |
| Texto completo: | https://hdl.handle.net/10216/136282 |
| País: | Portugal |
| Oai: | oai:repositorio-aberto.up.pt:10216/136282 |